VistaGen Therapeutics
VTGN
56 hedge funds and large institutions have $8.12M invested in VistaGen Therapeutics in 2026 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 14 closing their positions.
1,184% more call options, than puts
Call options by funds: $321K | Put options by funds: $25K
56% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 9
14% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 14
2.36% more ownership
Funds ownership: 34.82% → 37.18% (+2.4%)
2% more funds holding
Funds holding: 55 → 56 (+1)
8% less capital invested
Capital invested by funds: $8.84M → $8.12M (-$712K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$358K |
| 2 |
Two Sigma Investments
New York
|
+$167K |
| 3 |
Millennium Management
New York
|
+$142K |
| 4 |
VA
Verdad Advisers
Boston,
Massachusetts
|
+$112K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$92.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$155K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$117K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$101K |
| 4 |
OAC
OMERS Administration Corp
Toronto,
Ontario, Canada
|
-$68.4K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$52.4K |
VTGN Hedge Fund Activity: Q1 2026 in Review
56 of the 8,206 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q1 2026, worth a combined $8.12M — down 8.1% from $8.84M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new VTGN positions and 14 closed out — a net gain of 2 holders — while 14 added to existing stakes and 9 trimmed.
The largest buyer was Acadian Asset Management, opening a new position worth an estimated $358K. The largest seller was Jane Street, cutting an estimated $155K.
- 56 institutional investors held VistaGen Therapeutics (VTGN) as of Q1 2026, up from 55 in Q4 2025.
- Funds reported $8.12M of VistaGen Therapeutics stock for Q1 2026, down 8.1% quarter-over-quarter.
- 16 funds opened new VistaGen Therapeutics positions in Q1 2026 and 14 closed out, a net change of +2 holders.
- The largest VistaGen Therapeutics buyer in Q1 2026 was Acadian Asset Management, an estimated $358K added.
- The largest VistaGen Therapeutics seller in Q1 2026 was Jane Street, an estimated $155K sold.
Based on aggregated 13F filings for Q1 2026.